Evidence map›Paper›PMID 37707701›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2023

Efficacy and Safety of a Biosimilar Liraglutide (Melitide

Alireza Esteghamati, Mehran Zamanzadeh, Mojtaba Malek, Mohammad Khaledi, Arezoo Monavari, Laily Najafi, Zahra Banazadeh, Ramin Malboosbaf, Rokhsareh Aghili, Sedigheh Mahdikhah and 4 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03421119. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03421119 phase3unknown status

A Phase III, Randomized, Parallel, Double-blind, and Non-inferiority Clinical Trial to Compare Efficacy and Safety of CinnaGen-liraglutide to Innovator Liraglutide Product (Victoza®) in Patients With Type II Diabetes (T2D)

Ran2019Enrolled300Registered outcomes12Posted comparisons0ConditionsDiabetes Mellitus, Type 2ArmsLiraglutide 6 MG/ML Pen Injector, Metformin, Sulfonylurea/non-sulfonylurea insulin secretagogues
PMID 18931095PMID 19289857PMID 19515413PMID 19688338PMID 19317822other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Alireza EsteghamatiEndocrinology and Metabolism Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Mehran ZamanzadehEast Tehran Diabetes Association, Tehran, Iran.
Mojtaba MalekResearch Center for Prevention of Cardiovascular Disease, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Mohammad KhalediIran University of Medical Sciences, Tehran, Iran.
Arezoo MonavariBahar Clinic, Karaj, Alborz, Iran.
Laily NajafiEndocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS), No. 10, Firoozeh St, Vali-asr Ave, Vali-asr Sq, Tehran, 1593716615, Iran.
Zahra BanazadehEndocrine Research Center, Iran University of Medical Sciences, Tehran, Iran.
Ramin MalboosbafInternal Medicine and Endocrinology, Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.
Rokhsareh AghiliEndocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS), No. 10, Firoozeh St, Vali-asr Ave, Vali-asr Sq, Tehran, 1593716615, Iran.
Sedigheh MahdikhahFirouzgar Endocrine Research Center, Diabetes Clinic, Iran University of Medical Sciences, Tehran, Iran.
Hasan Ganjizadeh-ZaverehDr. Ganjizadeh's Clinic, Yousefabad, Tehran, Iran.
Hamidreza KafiMedical Department, Orchid Pharmed Company, Tehran, Iran.
Farhad HosseinpanahObesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mohammad Ebrahim KhamsehEndocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences (IUMS), No. 10, Firoozeh St, Vali-asr Ave, Vali-asr Sq, Tehran, 1593716615, Iran. m.e.khamseh@gmail.com.ORCID http://orcid.org/0000-0003-4313-8440
Iran University of Medical Sciences · IRIranian Orthopedic Association · IRResearch Institute for Endocrine Sciences · IRTehran University of Medical Sciences · IR

Funding

CinnaGen 702/396
6 · The paper itself

Abstract

introductionLiraglutide effectively controls blood glucose level and reduces body weight. The aim of this study was to compare the efficacy and safety of a biosimilar liraglutide (Melitide

methodsIn this phase 3 clinical noninferiority trial, adult patients with inadequately controlled T2DM and with hemoglobin A

resultsOf the 300 participants enrolled in this study, 235 were included in the per-protocol analysis (112 in the Melitide

conclusionThe biosimilar liraglutide (Melitide

trial registrationNCT03421119.

Indexed as

BiosimilarDiabetesLiraglutideMelitide®Victoza®

Identifiers

PMID37707701
PMCPMC10570258
OpenAlexW4386725566

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.